Pelvic inflammatory disease is a risk factor for cervical cancer

European Journal of Gynaecological Oncology

Volumn 24, Issue 5, 2003, Pages 401-404

  Skapinyecz, J ^a   Smid, I ^a   Horvath A ^b   Jeney, Cs ^c,d   Kardos, L ^e   Kovacs L ^e  

^a Kenezy Korhaz Rendelointezet   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c H MED Ltd   (Hungary)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^e UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cervical cancer; Human papillomaviruses; Pelvic inflammatory disease; Polymerase chain reaction

Indexed keywords

ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PELVIC INFLAMMATORY DISEASE; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0141987546     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. World Health Organization: Health for All Dataset, www.who.ch.
2. Editorial commentary: "The EU's answer to future public-health challenges". Lancet, 359, 2211, 2002.
3. Cuzick J., Szarewski A., Terry G., Ho L., Hanby A., Maddox P, et al.: "Human papillomavirus testing in primary cervical screening". Lancet, 1995, 345, 1533.
4. Meijer C.J., Helmerhorst T.J., Rozendaal L., van der Linden J.C., Voorhorst F.J., Walboomers J.M.: "HPV typing and testing in gynaecological pathology: has the time come?". Histopathology, 1998, 33, 83.
5. Josefsson A.M., Magnusson P.K., Ylitalo N., Sorensen P., Qwarforth-Tubbin P., Andersen P.K.: "Viral load of human papiliomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study". Lancet, 2000, 355, 2189.
6. Meijer C.J., Rozendaal R., Walboomers J.M.: "Clinical role of HPV testing". In: "Global challenge of cervical cancer screening and prevention". J. Monsonego (ed.). CME J. Gynecol. Oncol., 2000, 5, 14, 26.
7. Jacobs M.V., Walboomers J.M., Snijders P.J., Voorhorst F.J., Verheijen R.H., Fransen-Daalmeijer N., Meijer C.J.: "Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age related patterns for high-risk and low-risk types". Int. J. Cancer, 2000, 87, 221.
8. Report of the US Preventive Services Task Force: "Guide to Clinical Preventive Services". Baltimore, Williams and Wilkins, 1989.
9. Chiarini F., Pisani S., Gallinelli C., Papi E., Seganti L., Degener A.M. et al.: "Simultaneous detection of HPV and other sexually transmitted agents in chronic urethritis". Minerva Urol. Nephrol., 1998, 50, 225.
10. Giraud J., Coiffic J., Poulain P., Kerisit J.: "High prevalence of cervical intra-epithelial neoplasia in women treated for pelvic inflammatory disease". Eur. J. Obstet. Gynecol. Reprod. Biol., 1998, 81, 51.
11. Briggs R.M., Holmes K.K., Kiviat N., Barker E., Eschenbach D.A., De Yong R.: "High prevalence of cervical dysplasia in STD clinic patients warrants routine cytologic screening". Am. J. Public. Health., 1980, 70, 1212.
12. Becker T.M., Wheeler C.M., McGough N.S.: "Sexually transmitted diseases and other risk factors for cervical dysplasia among south-western hispanic and non-hispanic white women". J. Am. Med. Assoc., 1994, 271, 1181.
13. Kamb M.L.: "Cervical cancer screening of women attending sexually transmitted disease clinics". Clin. Infect. Dis., 1995, 20 (suppl. 1), S98.
14. Boom R., Sol C.J., Salimans M.M., Jansen C.L., Wertheim-van Dillen P.M., van der Noordaa J.: "Rapid and simple method for purification of nucleic acids". J. Clin. Microbiol., 1990, 28, 495.
15. Farrell D.J.: "Evaluation of AMPLICOR Neisseria gonorrhoeae PCR using cppB nested PCR and 16S rRNA PCR". J. Clin. Microbiol., 1999, 37, 386.
16. Catry M.A., Borrego M.J., Cardoso J., Ázevedo J., Santo I.: "Comparison of the Amplicor Chlamydia trachomatis test and cell culture for the detection of urogenital chlamydial infections". Genitourin Med., 1995, 71, 247.
17. Blanchard A., Crabb D.M., Dybvig K., Duffy L.B., Cassell G.H.: "Rapid detection of tetM in Mycoplasma hominis and Ureaplasma urealyticum by PCR: tetM confers resistance to tetracycine but not necessarily to doxycycline". FEMS Microbiol. Lett., 1992, 74, 277.
18. Grodstein F., Tothman K.J.: "Epidemiology of pelvic inflammatory disease". Epidemiology, 1994, 5, 234.
19. Cox J.T.: "Epidemiology of cervical intra-epithelial neoplasia: the role of human papillomavirus". Clin. Obstet. Gynecol., 1995, 9, 1.
20. Bornstein J., Rahat M.A., Abramovici H.: "Etiology of cervical cancer: current concepts". Obstet. Gynecol. Surv., 1995, 50, 146.
21. Duggan M.A.: "Human papillomaviruses in gynecological cancer". Curr. Opin. Obstet. Gynecol., 1996, 8, 56.
22. Lehtinen M., Dillner J., Knekt P. et al.: "Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma". Br. Med. J., 1996, 312, 537.
23. Dillner J., Lehtinen M., Bjørge T. et al.: "Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer". J. Natl. Cancer Inst., 1997, 89, 1293.
24. Koskela P., Anttila T., Bjørge T. et al.: "Chlamydia" trachomatis infection as a risk for invasive cervical carcinoma". Int. J. Cancer., 2000, 85, 35.
25. Anttila T., Saikku P., Koskela P. et al.: "Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma". JAMA, 2001, 285, 47.